Elvucitabine

Overview of the antiretroviral drug Elvucitabine

Elvucitabine
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Elvucitabine is an antiretroviral drug used in the treatment of HIV/AIDS. It is a nucleoside reverse transcriptase inhibitor (NRTI), which works by inhibiting the action of reverse transcriptase, an enzyme crucial for the replication of HIV.

Mechanism of Action

Elvucitabine is a synthetic analog of lamivudine, another NRTI. It competes with the natural substrate, deoxycytidine triphosphate, for incorporation into the viral DNA by reverse transcriptase. Once incorporated, it causes chain termination, thereby preventing the synthesis of viral DNA and subsequent replication of the virus.

Pharmacokinetics

Elvucitabine is administered orally and is well absorbed from the gastrointestinal tract. It has a long half-life, which allows for once-daily dosing. The drug is primarily excreted unchanged in the urine, indicating minimal metabolism.

Clinical Use

Elvucitabine is used in combination with other antiretroviral agents for the treatment of HIV-1 infection. Its use is particularly considered in patients who have developed resistance to other NRTIs.

Side Effects

Common side effects of Elvucitabine include nausea, headache, and fatigue. As with other NRTIs, there is a risk of lactic acidosis and hepatomegaly with steatosis, which are serious but rare side effects.

Development and Approval

Elvucitabine was developed as a potential treatment for HIV due to its potent activity against the virus and its ability to overcome resistance seen with other NRTIs. However, as of the latest updates, it has not been widely approved for clinical use in many countries.

Related pages

• HIV/AIDS
• Antiretroviral drug
• Nucleoside reverse transcriptase inhibitor
• Lamivudine

• 
  Elvucitabine